Loxstar for Hair Regrowth - Quick Reference Sheet
evipedia.ai ← Back

Loxstar for Hair Regrowth

Created on 07/03/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Loxstar is an early-stage scalp treatment for pattern hair loss, acting through a signaling route different from the two better-known options. Its main claimed benefit — more visible hairs — rests on small, mixed studies, and any gains look modest. Scalp irritation is the most consistent concern. It stays investigational and hard to obtain reliably. (Full Review)

Protocol

Regimen
Once daily topical
Low-concentration solution or foam to the defined balding region
Strategy
Monotherapy or combination
Standalone, or added to topical minoxidil and/or an oral hormone-pathway agent
Best time of day
Evening
When the scalp can remain undisturbed; reduces transfer to pillows, hands, and face
Time to effect
Visible change
16–24 weeks
Sustained trial needed before meaningful assessment
Early weeks
Little or none
May show minimal change or transiently increased shedding
First reassessment
12 weeks
Repeat standardized photography and trichoscopy in the marked area

Benefits

Contraindications
  • Pregnancy (any gestational age) or breastfeeding
  • Known hypersensitivity to prostaglandin analogs
  • Active, broken, or infected scalp skin (until resolved)
  • Moderate-to-severe active scalp dermatitis (until healed)
    •
Key Interactions
  • Other topical scalp prescriptions (topical corticosteroids, topical minoxidil)
  • OTC scalp topicals (ketoconazole or salicylic-acid shampoos, exfoliants, retinoids)
  • Additive hair-growth agents (topical minoxidil, rosemary oil, caffeine scalp products)
  • Procedural scalp treatments (microneedling, laser therapy)
  • Oral hair supplements (biotin, saw palmetto, collagen)
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: Local scalp irritation
    •
  • Low: Unwanted hair growth at application margins; skin pigmentation changes
    •
  • Speculative: Systemic prostaglandin effects; paradoxical shedding on initiation
    •

Monitoring

Marker Target Why
Ferritin (iron stores) 40–70 ng/mL Low iron stores drive shedding and blunt regrowth
TSH 1.0–2.0 mIU/L Thyroid dysfunction is a common reversible cause of hair loss
Vitamin D (25-hydroxyvitamin D) 40–60 ng/mL Low vitamin D is associated with several forms of hair loss
Serum zinc 90–120 µg/dL Zinc deficiency contributes to hair shedding
ALT ≤25 U/L (women), ≤30 U/L (men) Baseline liver enzyme reassurance given minor CYP2C9 metabolism

Cadence: Baseline, then reassess at 12 weeks, 24 weeks, and every 6 months thereafter

Qualitative Assessment

  • Perceived hair density and coverage — whether the treated area looks and feels fuller over months
  • Daily shedding — whether hair lost during washing and brushing decreases
  • Scalp comfort — absence of persistent redness, itching, or burning
  • Confidence and satisfaction — the user's own sense of whether visible results justify continued use
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.